Welcome to the international HTA database

Showing [21342 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: use of healthcare services by people with confirmed SARS-CoV-2 infection and those with no documented evidence of infection]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: pediatric cancer predisposition using next-generation sequencing panels]
2023	Agency for Healthcare Research and Quality (AHRQ)	Use of telehealth during the COVID-19 era
2023	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for metastatic bone disease: effectiveness and harms
2023	Agency for Healthcare Research and Quality (AHRQ)	Postpartum care up to 1 year after pregnancy: a systematic review and meta-analysis
2023	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD repository evidence base
2023	Agency for Healthcare Research and Quality (AHRQ)	Partial breast irradiation for breast cancer
2023	Agency for Healthcare Research and Quality (AHRQ)	Nutrition as prevention for improved cancer health outcomes
2023	Agency for Healthcare Research and Quality (AHRQ)	Nonemergent percutaneous coronary intervention versus optimal medical treatment for stable ischemic heart disease: a rapid response literature review
2023	Agency for Healthcare Research and Quality (AHRQ)	Measuring healthcare organization characteristics in cancer care delivery research
2023	Agency for Healthcare Research and Quality (AHRQ)	Management of postpartum hypertensive disorders of pregnancy
2023	Agency for Healthcare Research and Quality (AHRQ)	Living systematic review on cannabis and other plant-based treatments for chronic pain
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those undergoing insertion of implantable cardiovascular devices
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those receiving chemotherapy for cancer
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023	Norwegian Institute of Public Health (NIPH)	[Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Invasive electroencephalography for drug-resistant epilepsy]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Triple-phase computed tomography in patients with liver lesion]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sapropterin in patients with phenylketonuria]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Holmium laser in non-prostate endourologic conditions]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lecanemab in Alzheimer’s Disease]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty and stenting in patients with carotid artery stenosis]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in psychiatry]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in respirology]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in pediatrics]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in neurology]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in internal medicine]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in hematology/oncology]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in general surgery]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023	Health Information and Quality Authority (HIQA)	Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023	Health Information and Quality Authority (HIQA)	Interventions to improve long COVID symptoms: a systematic review
2023	Health Information and Quality Authority (HIQA)	A slot-scanning, biplanar, digital X-ray imaging system for the evaluation and monitoring of orthopaedic conditions: evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision
2023	Adelaide Health Technology Assessment (AHTA)	Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
2023	Adelaide Health Technology Assessment (AHTA)	Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
2023	Adelaide Health Technology Assessment (AHTA)	Whole genome sequencing for the diagnosis of mitochondrial disease
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: An overview of precision medicine initiatives here and elsewhere]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: overview of interventions addressed by some evaluation agencies outside Quebec - an exploration of the diversity of potential evaluation topics]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Nurse-driven protocols for antibiotic initiation in febrile neutropenia
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Electrical auricular vagus nerve stimulation for pain
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Bleomycin electrosclerotherapy for vascular anomalies
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous aspiration thrombectomy for pulmonary embolism
2023	Austrian Institute for Health Technology Assessment (AIHTA)	177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Radiofrequency denervation for chronic lumbar or cervical spine pain]
2023	NIHR Health Services and Delivery Research programme	The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2023	NIHR Health Services and Delivery Research programme	Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation
2023	NIHR Health Services and Delivery Research programme	New and emerging technology for adult social care - the example of home sensors with artificial intelligence (AI) technology
2023	NIHR Health Services and Delivery Research programme	Early evaluation of the Children and Young People's Mental Health Trailblazer programme: a rapid mixed-methods study
2023	NIHR Health Services and Delivery Research programme	Towards achieving interorganisational collaboration between health-care providers: a realist evidence synthesis
2023	NIHR Health Services and Delivery Research programme	Thinking ahead about medical treatments in advanced illness: a qualitative study of barriers and enablers in end-of-life care planning with patients and families from ethnically diverse backgrounds
2023	NIHR Health Services and Delivery Research programme	A multimethod study of NHS 111 online
2023	NIHR Health Services and Delivery Research programme	Factors which facilitate or impede patient engagement with pulmonary and cardiac rehabilitation: a rapid evaluation mapping review
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: rapid assessment zones in emergency departments - organizational characteristics and their impact]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023	NIHR Health Technology Assessment programme	Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: developing portraits to support the ongoing adaptation of youth services by local service networks]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevant practices for promoting hearing health in long-term residential care settings]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Prolastin-C Liquid – congenital alpha1-antitrypsin deficiency]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Glassia – congenital alpha1- antitrypsin deficiency]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2023	Scottish Health Technologies Group (SHTG)	Technology enabled theatre scheduling tools
2023	The Federal Joint Committee (G-BA)	Pharmaceutical Directive/Annex XII: Brexucabtagen Autoleucel (new therapeutic indication: relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, 26 years of age and above)
2023	Health Sciences Institute in Aragon (IACS)	[Effectiveness, safety and efficiency of subconjunctival drainage devices using an ab-internal approach for primary open-angle glaucoma surgery]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: evaluation and implementation of digital health solutions - a look at user participation]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid for ablation in cardiac arrhythmia]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid for defibrillators and pacemakers]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Current scientific knowledge on myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS)]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V - Third addendum to Commission H20-02]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olopatadine/mometasone furoate (allergic rhinitis) - Addendum to Commission A22-125]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ciltacabtagene autoleucel (multiple myeloma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fenfluramine (Lennox-Gastaut syndrome, add-on therapy, = 2 years) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Maralixibat (cholestatic pruritis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Valoctocogen roxaparvovec (haemophilia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cold plasma in wound therapy (2nd addendum to Commission E21-03)]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cold plasma in wound therapy]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daridorexant (insomnia) - Addendum to Commission A22-123]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/abacavir/lamivudine (HIV infection in children) - Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Voclosporin (lupus nephritis) - Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Finerenone (CKD stage 2 and 3) - Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Finerenone (CKD stage 1 and 2) - Benefit assessment according to §35a Social Code Book V]